Tumour necrosis factor-x was discovered in tumour-bearing mice as an endotoxin-induceable serum factor causing 'haemorrhagic' tumour necrosis (Carswell et al., 1975) . Genetic sequence analysis indicated that TNF and cachectin, a serum factor which can cause wasting in chronic disease, are identical molecules (Beutler & Cerami, 1986) . Considering antitumour mechanisms only, cytostatic or cytolytic activities are already evident in vitro (Sugarman et al., 1985; Creasey et al., 1987; Lewis et al., 1987) . In vivo, TNF-x may indirectly enhance its antitumour effect via incompletely characterised vascular actions (Manda et al., 1987; Watanabe et al., 1988a) . Probably, both mechanisms can lead to tumour regression (Shimomura et al., 1988) . On the other hand, TNF-a can promote angiogenesis in living tissues even though it inhibits endothelial cell growth in vitro (Frater-Schroeder et al., 1987; Leibovich et al., 1987) . These partly contradictory findings finally all imply changes of the nutritive tumour perfusion which in turn dictates therapeutically relevant parameters of the cellular micromilieu (Kallinowski et al., 1989) . Thus, different TNF-related flow variations might at least partially explain an inconsistent effectiveness of TNF in the clinical situation (Spriggs et al., 1987) . In a step towards further understanding TNF actions we have examined the response of tumour perfusion and proliferation to various TNF doses. Changes in the metabolism of tumour cells (02 and glucose uptake, lactate release, extracellular pH) were also followed during TNF treatment. A better knowledge of TNF effects might provide a rationale for combination with other treatment modalities including radiation, chemotherapy and hyperthermia (Selby et al., 1987) .
Materials and methods

Animals
Sprague-Dawley rats were bred and maintained in the Department of Applied Physiology (University of Mainz, FRG). The animals were kept in pairs in Macrolon cages with dust-free wood bedding. They fed on Altromin 1324 standard diet for rats (Altromin, Lage/Lippe, FRG) and water ad libitum. Room temperature was adjusted to 22 ± 1°C at a relative humidity of 55 ± 5% (12 h light/dark cycles). Tumour DS-carcinosarcoma cells were serially passaged in the peritoneal cavity of SD-rats. TNF-sensitivity in viiro was tested using DS-carcinosarcoma cells in suspension culture (RPMI 1640 medium, Sigma Chemicals, St Louis, MO, USA; 5% CO2 in air; 10% fetal calf serum, Gibco BRL, Bethesda, MD, USA). 104 cells were plated into microtitre wells 12 h before various TNF concentrations were added. The specific activity of rhTNF-a was 6.6 x 106 U mg protein-' (BASF/ Knoll AG, Ludwigshafen, FRG). The mean endotoxin level was < 0.025 ng mg protein-' as determined by Limulus amoebocyte lysate assay. After 48 h, cell density was evaluated. Reduction of growth by 50% was found at 100 ng rhTNF-x ml-' (L929 cells: approx. I ng TNF ml-'; MCF-7 cells: approx. 10 ng TNF ml-'). Consequently, DScarcinosarcoma cells were classified as moderately TN Fsensitive according to Creasey cl al. (1987) .
Investigations on ascites tumours Tumours were implanted by i.p. injection of 0.7 ml ascites (approx. 107 cells ml-'). rhTNF-a (1-1000 lg kg-body weight in 1 ml PBS) was given every 12 h i.p. beginning 8 h after tumour implantation. Injections of PBS served as control. After a growth period of 6 days, i.e. at the end of the exponential growth period of control tumours, the animals were killed by cervical dislocation and weighed before and after complete removal of the ascites from the peritoneal cavity. The total amount of ascites was obtained as the difference of both measurements. The percentage of cells in the ascitic fluid was determined by microcapillary centrifugation, and the cellular wet weight was calculated. Investigations on solid tumours Volume growth curves of DS-carcinosarcoma, implanted into the subcutis of the hind foot dorsum (s.c. injection of 0.4 ml ascites; approx, I07 cells ml-') were obtained by daily measurements of the three orthogonal diameters and subsequent calculation of an ellipsoid. Tumour-bearing animals were treated with daily injections of rhTNF-a (1 -1000 #g kg-' body weight) into the tail vein starting 24h after tumour implantation. PBS injections were used as controls.
In a separate series, tumour blood flow was determined using the krypton-85 clearance technique (Vaupel et al., 1977) . Here (Vaupel et al., 1977) . In a first step, blood flow changes were evaluated 4 h after single TNF doses (I gg to 1 mg rhTNF-ax kg-' i.v.; average tumour size approx. 1.0 g). Then, possible influences of tumour size on flow reduction after high TNF doses (1 mg rhTNF-a kg-' i.v.) were investigated using small and larger DS-carcinosarcomas (tumour sizes around 0.6 and 1.3 g, respectively). Next, the time course of a possible flow decrease was evaluated. Here, blood flow was measured before and in 30 min intervals up to 4 h after i.v. injection of rhTNF-a (1 mg kg-' in 1 ml PBS) or PBS (1 ml kg-'). In a final series, the effect of repeated treatment with rhTNF-x on tumour blood flow was assessed (mean tww: 0.6-1.0 g; growth period: 6-8 days). Since tumour blood flow critically depends on tumour size, PBS-treated tumours of similar sizes (tumour age: 7.0 ± 0.3 days, tww: 0.8 ± 0.1 g) were used as controls.
Efje(t of rh TNF-a on liver and kidney blood flow Acute changes of normal organ blood flow were evaluated 4 h after i.v. injection of high TNF doses (1 mg kg-'). Liver perfusion was determined by "5Kr clearance (Vaupel et al., 1978) . Global kidney perfusion was measured after cannulation of the renal vein by timed collection of the venous outflow (Guenther et al., 1974; Arendshorst et al., 1975) . As controls, both untreated and PBS-treated animals in (1 ml kg-' bw i.v.) were used.
Statistical evaluation
Descriptive statistical parameters were routinely calculated. Two-tailed t test and Mann-Whitney U test were used for evaluation of statistically significant differences between various treatment groups. In the following, means ± s.e. are given if not indicated otherwise.
Results
EfJect ol TNF on asc-ites tumours Tumour growth was markedly reduced after treatment with high TNF doses (0.1 and 1.0 mg kg-' i.p.). Administration of low TNF doses (1 and 10 jig kg-' i.p.) was followed by a slight increase both in the ascitic volume and in the total weight of the ascites cells (Figure 1) . Similarly, the absolute number of ascites cells was significantly decreased after treatment with high TNF doses (P<0.01, Table I ). After treatment with small TNF doses, cell numbers varied only slightly compared to control counts (Table I) .
The growth changes were concomitant with an immigration of host cells into the ascites and an accumulation of tumour cell debris (Table I, Figure 2) . Hereby, small TNF doses already led to morphological changes and the disruption of tumour cell membranes. The pronounced invasion of micro-and macrophages into the peritoneal cavity at high TNF doses probably contributed to the destruction of tumour cells. Cellular TNF effects were further evidenced by monitoring the diameters of malignant cells. During control conditions, the mean cell diameter is 28.7 ± 0.7 ,.m. The intraperitoneal application of small TNF doses reduced this value to 26.3 + 0.9, to 25.3 ± 0.7 and to 23.0 ± 0.9 gm at 1, 10 and 100ggkg-' TNF (P<0.005). Higher TNF levels were followed by an even more marked reduction to values of 21.0±0.5gim (P<0.0001). Growth changes upon TNF application were paralleled by alterations in oxygen consumption rates (Figure 3) . At higher TNF doses, a marked reduction of the 02 uptake was observed whereas the oxygen consumption was increased at low TNF doses. Only traces of glucose were found in the ascitic fluid in all treatment groups indicating an avid glucose consumption under all conditions. The production of lactate somewhat increased at low TNF dose levels. At higher TNF doses the reduction of growth rates was concomitant with a decreased lactate release leading to lower lactate levels in the ascitic fluid (Figure 4) . Extracellular pH values generally followed changes of the ascites lactate concentrations ( Figure   4 ). mours after a growth period of 7 days was 0.87 + 0.07 ml gmin ' . After daily application of lower TNF doses, an increased perfusion was observed (growth period: 6 days).
Here, TBF was 1.19 ± 0.10 ml g-' mmn after 1 ysg kg-',and 1.17±+0.08 mlg-min'} after l01tg kg1t Higher TNF doses retarded tumour growth as described above. Considering sizes comparable to that of control tumours, a slight reduction of tumour blood flow was obvious after application of Values are means ± s.e. *P<0.01; **P<0.0001. tion of perfusion pressure (124 ± 3 mmHg, P <0.05) whereas high TNF doses led to a MABP reduction (101 ± 2 mmHg, P<0.05).
The flow changes were found to be independent of the tumour size (0.5-1.3 g). Both in small and larger DS-carcino- growth factor for chronic B-cell malignancies (Cordingley et al., 1988 (Sugarman et al., 1985; Creasey et al., 1987) , action of activated host cells (Shau, 1988) , a modulation of tumourspecific immunity (Talmadge et al., 1988) (Tracey et al., 1986) . The flow reduction observed after single administration of high TNF doses can be caused by both systemic and tumour-specific mechanisms. A flow chart depicting possible pathways is given in Figure 7 . Considering systemic effects, high TNF doses are followed by a reduction of perfusion pressure which could indicate the initiation of a 'septic shock syndrome' (Tracey et al., 1986 (Nawroth et al., 1986; Shimomura et al., 1988) . The stimulation of polymorphonuclear leukocytes and macrophages (Shau, 1988) , the binding of activated neutrophils to endothelial cells (Gamble et al., 1985) , endothelial cell damage (Movat et al., 1987) , and the release of procoagulant activity (Nawroth et al., 1986; Bevilacqua et al., 1986) and of interleukin-I (Locksley et Kurt-Jones et al., 1987) are pathophysiological mechanisms involved in vascular damage.
After repeated application of low TNF doses, an increased tumour perfusion concomitant with a rise in perfusion pressure was noted. After high TNF doses, tumours shrank to such small sizes that valid perfusion measurements could not be performed. The reduction in tumour volume might be due to sustained vascular damage or due to cellular effects discussed above.
So far, phase I clinical trials with TNF doses ranging from 1-7.5 tLg kg-' i.v. indicate only limited efficacy of TNF monotherapy (Conkling et al., 1988; Herrmann & Mertelsmann, 1989) . Dose-limiting side effects in patients include pyrexia and hypotension. In rodents, similar side effects of TNF were observed (Tracey et al., 1986) . In our system, single application of rhTNF-a at a dose of 1 mg kg-' i.v. was lethal for about 10% of the animals. Histological examination after 6[Reduction of tumour blood flow Figure 7 Relevant pathophysiological mechanisms involved in reduction of tumour blood flow after TNF treatment.
IN VIVO TARGETS OF rhTNF-a 559 TNF treatment suggests that the gastrointestinal tract is more TNF sensitive than other tissues (Remick et al., 1987) . Partial tolerance to the gastrointestinal effects of high rh-TNF-a doses developed when TNF application was repeated daily (Patton et al., 1987) . In good agreement with these data haemorrhagic diarrhoea with weight loss developed only after the first TNF application. Furthermore, blood flow of liver or kidney was not altered after single application of high TNF doses indicating that, at that time, severe vascular damage in these organs is unlikely.
The decrease of nutritive blood flow through malignant tumours leads to ischaemic changes, and to a distinct worsening of the supply of nutrients and of the energy status of these tumours, thus contributing to cell killing (Shine et al., 1989) . Furthermore, the changes of the tumour perfusion and of the regional micromilieu might have sustained impact on possible combinations with other non-surgical treatment modalities. The reduction of tumour blood flow markedly influences the intratumour pharmakokinetics of antiproliferative agents and is thus critical for a possible combined treatment. On the other hand, hyperthermia applied either locally (Kallinowski et al., 1988) or as whole body treatment (Haranaka et al., 1987; Watanabe et al., 1988b ) may benefit from a preceding TNF application. It is most likely that an increased oxygen consumption at low TNF doses or a decreased oxygen supply after treatment with high TNF dose levels worsen tumour tissue oxygenation and thus induce radiation resistance in vivo. In vitro, no significant benefit of a combination of radiation therapy and TNF treatment is evident (Chang & Keng, 1988) .
Similar to other lymphokines, there is some specificity of TNF actions in various species (Fransen et al., 1986) . We chose rats as our tumour hosts since they permit the investigation of TNF effects in vivo over a wide dose range (Tracey et al., 1986) . It has been demonstrated that speciesspecificity can lead to an underestimation of the biological potency of TNF-a from heterologous sources (Kramer et al., 1988) . Thus, use of recombinant TNF from rat rather than from human sources might alter quantitative values of the data presented here, but will probably not alter the qualitative mechanisms evaluated.
